A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy
Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, Oyee J, Boland A, Dickson R, Dundar Y, Boyle R
Record ID 32011001140
English
Authors' recommendations:
Study found that the current use of Pharmalgen® venom immunotherapy in clinical practice in the NHS appears to be based on limited and poor-quality clinical effectiveness research. Pharmalgen® may be cost-effective for a subgroup of patients at high risk of future stings and a subgroup in whom Pharmalgen® improves quality of life owing to reduced anxiety.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.hta.ac.uk/2448
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antigens, Dermatophagoides
- Bee Venoms
- Hypersensitivity
- Wasp Venoms
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2012 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.